Deal memos, portfolio updates, platform reviews, and education — all documented in public.
The April 2026 investment. A $17M revenue fair trade beauty brand with 3x YoY growth, 4,400+ retail doors, and a founder who previously built a company to $40M+ revenue. Entry valuation: 1.28x TTM revenue.
Seven positions, $2,786 deployed, all showing positive momentum. This month's standouts: tapouts hits $5.5M ARR with 174% year-over-year growth, and Koios Medical joins the Harrison.ai Open Platform Ecosystem. Full position-by-position breakdown with sourced facts, editorial read, and a new scoring rubric.
The May 2026 investment. A live group coaching platform for children's mental health with $5.5M ARR, 174% YoY growth, and a model that solves a problem 34 million American kids have right now.
In March I invested in tapouts. Four other companies made the shortlist. One was the highest-scoring deal in SBC history. Here is the full reasoning behind every pass — including the one that still bothers me.
Koios Medical is an FDA-cleared AI platform that helps radiologists detect breast cancer earlier and more accurately. Here is my full one-page thesis on why I deployed $500 via WeFunder in February 2026 — and why I chose it over three other live deals.
In October 2025, I invested £198 (~$250) in FanHub via Crowdcube. A UK-based fan loyalty platform rewarding match-going football supporters with pints, tickets, and experiences. Here is why a sports business executive with 20 years in the industry found this worth backing.
In September 2025, I invested $310.50 in Numurus via StartEngine. An edge AI platform that lets engineers build autonomous robotic systems in weeks instead of years. Here is the thesis — and why a $10.78M valuation for a company with NVIDIA, Qualcomm, and Vecow partnerships felt like a reasonable entry.
In September 2025, I invested $259.81 in Chi Chi's Restaurants via StartEngine. I will tell you upfront: this was not a framework decision. It was a nostalgia bet. Here is the honest accounting of why I made it — and what it taught me about the difference between investing and remembering.
In February I deployed £500 into Koios Medical. Four other companies made it deep into the screening process before I passed. Here is the full reasoning behind each decision — including two I genuinely wanted to invest in but couldn't.
In April 2021, I invested $100 in COI Energy via Republic. It was the smallest cheque I have ever written on an investment. Here is the thesis I made to myself at the time — and an honest retrospective on what has happened since.
In April 2021, I invested $1,035 in Sugarfina via StartEngine. It was my largest single position, and I made it before I had a formal screening process. Here is the case I made to myself at the time — and an honest retrospective on what I got right, what I missed, and where the investment stands five years later.
I've invested on all three major US equity crowdfunding platforms. Here's an honest comparison of the investor experience, deal quality, and key differences.
KingsCrowd is the closest thing equity crowdfunding has to a Morningstar rating. Here's how the scoring system works and how I use it as a primary screening tool.
Most people think startup investing is only for Silicon Valley insiders. Equity crowdfunding changed that. Here's why I decided to document the journey publicly — losses and all.
